The stock of Iterum Therapeutics Plc (ITRM) has seen a 8.76% increase in the past week, with a 9.28% gain in the past month, and a -4.50% decrease in the past quarter. The volatility ratio for the week is 5.61%, and the volatility levels for the past 30 days are at 5.05% for ITRM. The simple moving average for the past 20 days is 6.85% for ITRM’s stock, with a -21.00% simple moving average for the past 200 days.
Is It Worth Investing in Iterum Therapeutics Plc (NASDAQ: ITRM) Right Now?
The 36-month beta value for ITRM is also noteworthy at 2.87. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 2 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for ITRM is 39.13M, and at present, short sellers hold a 2.98% of that float. The average trading volume of ITRM on July 10, 2025 was 539.63K shares.
ITRM) stock’s latest price update
The stock price of Iterum Therapeutics Plc (NASDAQ: ITRM) has jumped by 13.61% compared to previous close of $0.93. Despite this, the company has seen a gain of 8.76% in its stock price over the last five trading days. globenewswire.com reported 2025-07-02 that DUBLIN and CHICAGO, July 02, 2025 (GLOBE NEWSWIRE) — Iterum Therapeutics plc (Nasdaq: ITRM) (“Iterum” or the “Company”), a company committed to delivering next generation oral and IV antibiotics to address infections caused by multi-drug resistant pathogens, today announced that it has granted a non-statutory share option to purchase an aggregate of 200,000 ordinary shares of Iterum to Christine Coyne, Iterum’s newly appointed Chief Commercial Officer. This grant was awarded pursuant to the Nasdaq inducement grant exception as a component of new hire employment compensation.
Analysts’ Opinion of ITRM
H.C. Wainwright, on the other hand, stated in their research note that they expect to see ITRM reach a price target of $2.50. The rating they have provided for ITRM stocks is “Buy” according to the report published on March 15th, 2021.
RBC Capital Mkts gave a rating of “Sector Perform” to ITRM, setting the target price at $2 in the report published on June 02nd of the previous year.
ITRM Trading at 6.48% from the 50-Day Moving Average
After a stumble in the market that brought ITRM to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -64.90% of loss for the given period.
Stock Fundamentals for ITRM
The total capital return value is set at -0.55.
Currently, EBITDA for the company is -18.7 million with net debt to EBITDA at 0.8. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.72.
Conclusion
In summary, Iterum Therapeutics Plc (ITRM) has had a mixed performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
